Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Multiple Molecules See UK Prices More Than Double In December

18 Jan 2022

WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.

Scrip

Quick Listen: Scrip's Five Must-Know Things

17 Jan 2022

In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

Alaric DeArment 10 Jan 2022

CancerCells_Creations_223873720_1200x675

At the J.P. Morgan meeting, the company said its business development priorities have not changed, but it plans to prioritize licensing and small acquisitions rather than big ticket deals in 2022.

Pharmaceutical intelligence for consultancies

Your trusted pharma partner

Our unique strengths

Understand your clients’ world

Stay on top of the details

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product Brand List

HBW Insight: Health, Beauty and Wellness

Generics Bulletin

Pharma Intelligence latest insights

Multiple Molecules See UK Prices More Than Double In December

Quick Listen: Scrip's Five Must-Know Things

Gilead Aims For Oncology To Provide One-Third Of Revenues By 2030

Latest headlines

Coronavirus Update: Generics And Hurdles For Molnupiravir, More Japan Approvals

Euro Q4 Earnings Preview: GSK, Sanofi, Bayer And Reckitt

The Quality Lowdown: More Inspection Delays, More Findings On Sterility And Investigations

IP Questions Could Dog The WHO's BioHub Pandemic Project

Unilever’s Failed Bid Puts Pressure On GSK Spin-Out Plans

Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Not So Clean Beauty? False Advertising Lawsuits Cite PFAs Content In CoverGirl, BareMinerals Products

Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow

P&G’s String Of Cosmetic Brand Tuck-Ins Questioned During Q2 Call

Entry Reminder For Pharma Intelligence Awards Japan

ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates

UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy

Califf Confident Public Trust In US FDA Will Be Rebuilt

Scottish Funding OK For Breast Cancer Drugs Tukysa And Enhertu

Next steps

This is Contactus Section

Request a live demo

Speak to Sales

Client Services

Pharma Report Store